TYSABRI Rx

Select the drug indication to add to your list

TYSABRI

Colorectal disorders
Multiple sclerosis
Only 4 drugs may be compared at once

Generic Name and Formulations:

Natalizumab 300mg/15mL; soln for IV infusion after dilution; preservative-free.

Company:

Biogen

Select therapeutic use:

Indications for TYSABRI:

In moderately-to-severely active Crohn's disease: to induce and maintain clinical response and remission in adult patients with evidence of inflammation who have had inadequate response to or are intolerant to conventional therapy and TNF-α inhibitors.

Adult:

≥18yrs: Give by IV infusion over 1hr; monitor during and for 1hr post-infusion. 300mg every 4 weeks. Discontinue after 12 weeks of induction therapy if no therapeutic response, or if unable to taper off chronic concomitant steroids within 6 months of starting therapy. May continue with aminosalicylates.

Children:

<18yrs: not established.

Contraindications:

Progressive multifocal leukoencephalopathy (PML).

Warnings/Precautions:

Increased risk of PML with longer treatment duration (>2yrs), prior treatment with immunosuppressants, and/or presence of anti-JCV antibodies. Monitor for signs/symptoms of PML; withhold if develops. Test patients for anti-JCV antibody status prior to or during treatment if status unknown; patients with negative status should be retested periodically. Reevaluate periodically (at 3 months and 6 months post-infusion, every 6 months thereafter, and for at least 6 months after discontinuation). MS: obtain MRI scan prior to initiating therapy. Risk of JCV granule cell neuronopathy; manage similarly to PML if develops. Monitor for signs/symptoms of herpes encephalitis and meningitis; discontinue and treat if occurs. Refer for retinal screening if eye symptoms develop; consider discontinuing therapy if acute retinal necrosis is confirmed. Discontinue if jaundice or liver injury occurs. Immunosuppression. Monitor for infections. Vaccinations. Elderly. Pregnancy. Nursing mothers.

Interactions:

Concomitant other immunosuppressants or TNF-α inhibitors: not recommended.

Pharmacological Class:

Immunomodulator (integrin receptor antagonist).

Adverse Reactions:

Headache, fatigue, arthralgia, infections, depression, pain in extremity, abdominal discomfort, diarrhea NOS, nausea, rash; immune reconstitution syndrome (monitor), hypersensitivity reactions (discontinue if occurs; do not restart), hepatotoxicity, inj site reactions, antibody formation (if persistent, may substantially reduce efficacy), changes in blood cell counts.

Note:

This product is only available through the TOUCH prescribing program. For more information call (800) 456-2255.

REMS:

YES

Generic Availability:

NO

How Supplied:

Single-use vial—1

TYSABRI 15ml of 300mg/15ml vials (Qty:1)

appx. price $5817.00

Indications for TYSABRI:

Monotherapy for the treatment of relapsing forms of multiple sclerosis (MS).

Adult:

≥18yrs: Give by IV infusion over 1hr; monitor during and for 1hr post-infusion. 300mg every 4 weeks.

Children:

<18yrs: not established.

Contraindications:

Progressive multifocal leukoencephalopathy (PML).

Warnings/Precautions:

Increased risk of PML with longer treatment duration (>2yrs), prior treatment with immunosuppressants, and/or presence of anti-JCV antibodies. Monitor for signs/symptoms of PML; withhold if develops. Test patients for anti-JCV antibody status prior to or during treatment if status unknown; patients with negative status should be retested periodically. Reevaluate periodically (at 3 months and 6 months post-infusion, every 6 months thereafter, and for at least 6 months after discontinuation). MS: obtain MRI scan prior to initiating therapy. Risk of JCV granule cell neuronopathy; manage similarly to PML if develops. Monitor for signs/symptoms of herpes encephalitis and meningitis; discontinue and treat if occurs. Refer for retinal screening if eye symptoms develop; consider discontinuing therapy if acute retinal necrosis is confirmed. Discontinue if jaundice or liver injury occurs. Immunosuppression. Monitor for infections. Vaccinations. Elderly. Pregnancy. Nursing mothers.

Interactions:

Concomitant other immunosuppressants: not recommended.

Pharmacological Class:

Immunomodulator (integrin receptor antagonist).

Adverse Reactions:

Headache, fatigue, arthralgia, infections, depression, pain in extremity, abdominal discomfort, diarrhea NOS, nausea, rash; immune reconstitution syndrome (monitor), hypersensitivity reactions (discontinue if occurs; do not restart), hepatotoxicity, inj site reactions, antibody formation (if persistent, may substantially reduce efficacy), changes in blood cell counts.

Note:

This product is only available through the TOUCH prescribing program. For more information call (800) 456-2255.

REMS:

YES

Generic Availability:

NO

How Supplied:

Single-use vial—1

TYSABRI 15ml of 300mg/15ml vials (Qty:1)

appx. price $5817.00